Updates

A new chapter in clinical diagnostics has begun in New Zealand with the launch of Translyx Ltd, founded by Dr Ehsan Ullah, an Auckland-based physician scientist and healthcare entrepreneur. The company is on a mission to bring advanced diagnostic solutions that have been transforming healthcare globally directly into the New Zealand and Oceania markets.

Translyx will introduce technologies across critical areas including antibacterial resistance, sepsis, oncology biomarkers, point-of-care testing, cardiac biomarkers, and endocrine diagnostics. By bridging the gap between global innovation and local clinical practice, the company aims to support clinicians, laboratories, and healthcare providers with faster, more precise diagnostic tools that can improve patient care and outcomes.

This is just the beginning. Exciting announcements on partnerships, new technologies, and product launches are coming soon, as Translyx works to strengthen diagnostic capability across the region.

Keep an eye on this space for updates on how the company is helping bring the next generation of clinical diagnostics to New Zealand.

Translyx Limited was officially registered in New Zealand on 17 December 2025 and is preparing to commence operations in 2026. Our Research and Business Development teams are actively developing our product line and advancing our healthcare innovation pipeline over the next few months. Stay tuned for further updates here or contact us at info@translyx.co if you have any questions or would like to introduce your innovative healthcare product to the New Zealand market.